跳至主要内容
临床试验/NCT00432822
NCT00432822终止2 期

Double-Blind, Placebo Controlled, Multicentre Study With an Open Label Extension to Evaluate the Efficacy and Safety of Tetrahydrobiopterin (BH4) in Children and Adolescents With Hyperphenylalaninemia Caused by Phenylalanine Hydroxylase Deficiency

Orphanetics Pharma Entwicklungs GmbH0 个研究点目标入组 50 人开始时间: 2007年2月8日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
终止
发起方
入组人数
50
主要终点
dietary phenylalanine tolerance

研究概览

简要总结

The aim of the study is to confirm the efficacy and safety of BH4 in the treatment of hyperphenylalaninemia caused by phenylalanine hydroxylase deficiency in patients responsive to BH4. The primary objective is to assess the effect of BH4 on phenylalanine tolerance compared to placebo under optimal blood phenylalanine control and to demonstrate safety in 12 months long-term treatment. Additionally population PK will be assessed.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
— 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Female and male patients, aged 0-18 years
  • Phenylalanine-4-hydroxylase (PAH) deficiency shown by mutation analysis
  • Blood phenylalanine concentration in the target range under dietary treatment
  • Written consent of a parent or legal representative
  • Assumed availability within the period of study participation
  • Patients/parents willing and able to follow the recommended diet
  • Use of an effective method of contraception in female patients of child bearing potential

排除标准

  • BH4-deficiency due to genetic disorders in biosynthesis or recycling of BH4
  • History or current evidence of poor diet compliance
  • History or current evidence of clinically relevant allergic or idiosyncratic reactions to drugs or food
  • History of allergic reactions to BH4 or its excipients
  • Positive pregnancy test (ß-HCG in serum) and lactating females
  • Participation in other drug trials within the last 30 days before start for the study

结局指标

主要结局

dietary phenylalanine tolerance

safety

次要结局

未报告次要终点

研究者

发起方
Orphanetics Pharma Entwicklungs GmbH
申办方类型
Industry

相似试验